|
||||||||
|---|---|---|---|---|---|---|---|---|
| Basic information | ||||||||
| Chairman | President | Spokesperson | Telephone | Address | ESM Registration Date | |||
| Lester John Wu | LIN,MAO-YUAN | LIN,MAO-YUAN | 02-2503-5282 | 3F, No. 80, Sec. 1, Jianguo North Road, Zongshan Dist.Taipei , Taiwan | 2017/02/08 | |||
| Agent for litigious and non-litigious matters |
Tel of Agent for litigious and non-litigious matters |
Address of Agent for litigious and non-litigious matters |
||||||
| LIN,MAO-YUAN | 02-2503-5282 | 3F, No. 80, Sec. 1, Jianguo North Road, Zongshan Dist., Taipei 10491, Taiwan | ||||||
| Industrycategory | Key businesses | |||||||
| Biotechnology and Medical Care | (1)Gongwin Biopharm Holdings Corporation Ltd.has two subsidiaries, Gongwin Biopharm Corporation Ltd. and PTS International Incorporation. The first one is based in Taipei, Taiwan, which is engaged in cancer research, protocol designing/ conducting, manufacture process research, and market survey, being regarded as the headquarter of this corporate group. The latter one based in Texas, USA, has been conducting clinical trials in different countries. The PTS product pipelines are showed as below: ◎PTS302 applied to the therapy of lung cancer. ◎PTS100, focusing on the treatment of liver cancer. ◎PTS-02 has been approveed for orphan drug designation by USFDA . ◎PTS500, focusing on the malignant pleural effusion. (2)In near future, Gongwin will have the revenue from one of the pipelines by the licence-out model . A protocol of PTS-02 will be submitted to USFDA under the guidance of orphan drug. This is the outlook of ours. | |||||||
| Market info | |
|---|---|
| Latest trading info | Historic trading info |
| Financial data | |||
|---|---|---|---|
| Cash flows statement | Item | ||
| Amount(NTD, in thousands) | |||
| Cash flows from operating activities | |||
| Cash flows from investing activities | |||
| Cash flows from financing activities | |||
| Consolidated/Individual balance sheet |
Current assets | ||
| Non-current assets | |||
| Total assets | |||
| Current liabilities | |||
| Non-current liabilities | |||
| Total liabilities | |||
| Share capital | |||
| Capital surplus | |||
| Retained earnings | |||
| Other equity interest | |||
| Treasury shares | |||
| Total equity attributable to owners of parent | |||
| Non-controlling interests | |||
| Total equity | |||
| Book Value per share(NT$) | |||
| Consolidated/Individual profit and loss statement |
Operating revenue | ||
| Operating costs | |||
| Gross profit from operations | |||
| Operating expenses | |||
| Net other income (expenses) | |||
| Net operating income | |||
| Non-operating income and expenses | |||
| Profit before tax | |||
| Tax expense | |||
| Profit from continuing operations | |||
| Profit from discontinued operations | |||
| Profit | |||
| Other comprehensive income | |||
| Comprehensive income | |||
| Basic earnings per share | |||
Auditor's report on latest financial statements： auditor's report：